Product Pipeline
With medications in more than 4 therapeutic areas and over 15 products in just 5 years, Xeedia established itself as an industry leader. We’re dedicated to bringing the newest and most effective solutions and are always researching to create better and bigger ones.
The following table lists a selection of our product pipeline for the year
Linagliflozin
Pharmaceutical
Active
Linagliptin5MG
Empagliflozin10MG
Potential Indication
Status
Type 2 diabetes
Under Development
Business unit line
Cardio Metabolic
Therapeutic Area
Endocrine
Dosage form
Film coated tablet
Potential Indication
Status
Expected launch month
Type 2 diabetes
Under Development
Jan 2025
Linagliflozin
Pharmaceutical
Active
Linagliptin5MG
Empagliflozin25MG
Potential Indication
Status
Type 2 diabetes
Launched
Business unit line
Cardio Metabolic
Therapeutic Area
Endocrine
Dosage form
Film coated tablet
Potential Indication
Status
Expected launch month
Type 2 diabetes
Launched
Jan 2025
Diclopro 75MG SR
Pharmaceutical
Active
diclofenac sodium75MG
Potential Indication
Status
Osteoarthritis - RA -Arthritis flare ups - Gout
Under Development
Business unit line
orthopedic
Therapeutic Area
ANTIRHEUMATICS NON-S PLN
Dosage form
sustained release tablet
Potential Indication
Status
Expected launch month
Osteoarthritis - RA -Arthritis flare ups - Gout
Under Development
Jan 2025
Diclopro spray
Pharmaceutical
Active
diclofenac sodium4%
Potential Indication
Status
sprains - strains - low back pain - RA- OA
Under Development
Business unit line
orthopedic
Therapeutic Area
ANTIRHEUMATICS NON-S PLN
Dosage form
cutaneous spray solution
Potential Indication
Status
Expected launch month
sprains - strains - low back pain - RA- OA
Under Development
Feb 2025
Diclopro Relax
Pharmaceutical
Active
methocarbamol500MG
diclofenac50MG
Potential Indication
Status
Muscle relaxant - Muscle spasm
Under Development
Business unit line
orthopedic
Therapeutic Area
MUSCLE RELAXANTS, CENTRAL
Dosage form
Film coated tablet
Potential Indication
Status
Expected launch month
Muscle relaxant - Muscle spasm
Under Development
Jul 2025
Diclopro syp
Pharmaceutical
Active
diclofenac potassium2mg/ml
Potential Indication
Status
anti inflammatory - antipyretic - analgesic
Under Development
Business unit line
orthopedic
Therapeutic Area
ANTIRHEUMATICS NON-S PLN
Dosage form
Suspention
Potential Indication
Status
Expected launch month
anti inflammatory - antipyretic - analgesic
Under Development
Jul 2025
Diclopro Amp
Pharmaceutical
Active
diclofenac sodium75MG/3ML
Potential Indication
Status
osteoarthritis - RA -Arthritis flare ups - Gout- Acute musculoskeletal disorders
Under Development
Business unit line
orthopedic
Therapeutic Area
ANTIRHEUMATICS NON-S PLN
Dosage form
solution for IM injection or IV infusion
Potential Indication
Status
Expected launch month
osteoarthritis - RA -Arthritis flare ups - Gout- Acute musculoskeletal disorders
Under Development
Sep 2025
Newsletter